June 30, 2021
In the latest episode of the pharmaphorum podcast, pharmaphorum’s web editor Catherine Longworth speaks to Gerald Finken, the founder and CEO of RxE2.
The US-based company was founded in 2019 and is on a mission to bring the practice of pharmacy into clinical research.
May 28, 2021
In this latest podcast, pharmaphorum spoke to Andrew Meade, life sciences lead UK and Ireland at Accenture, about the trends that emerged in this year’s Q1 results season.
April 30, 2021
Episode 35 of the pharmaphorum podcast heard from Michael Smyth about Galapagos UK and joining the company as medical director just as COVID-19 hit.
April 20, 2021
In the latest episode of the podcast pharmaphorum’s website editor Catherine Longworth speaks with Dr. Darrin Disley, CEO of UK biotech Mogrify
March 31, 2021
In the latest episode of the podcast Dominic Tyer speaks with GlaxoSmithKline’s Philip Cruz about the discovery and commercialisation of new vaccines in the light of the pandemic.
March 23, 2021
This instalment of the podcast considers the meaning of digital innovation, both in pharma and outside the industry, and features digital transformation leader Edwin Erckens.
March 12, 2021
In episode 31 of the pharmaphorum podcast, Deep Dive editor George Underwood speaks to RedHill biopharma’s chief business officer Guy Goldberg about the potential for new COVID-19 therapeutics to help fight the pandemic and treat patients in the years to come.
March 8, 2021
Episode 3 of the Alderley Park Discovery Podcast covers how to successfully access life science funding and investment, highlighting a range of ways companies can attract investors.
In this instalment, Dominic Tyer is joined by Kinomica CEO Jane Theaker, BioCity investment director Claire Brown, Redx Pharma CEO Lisa Anson and Dr Kath Mackay, managing director at Bruntwood SciTech - Alderley Park.
February 26, 2021
For episode 30 I spoke with Dr Ashton Harper, who’s head of medical affairs in the UK and Ireland at Roche Diagnostics, about the pressure COVID-19 has put on healthcare systems.
A former NHS doctor, he noted how stressful and draining some days can be when working at healthcare’s frontline - even in normal times, and that the current fight against the pandemic brings little respite to staff.
February 12, 2021
In this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took over as CEO of gene therapy company Purespring Therapeutics earlier this month.
Francis was previously CEO of Sandoz, Novartis’ generics and biosimilars division, where he led the development of biosimilars and also sat on the Swiss pharma company’s executive committee.
January 29, 2021
The theme for episode 28 of the pharmaphorum podcast is diversity and inclusion in pharma, ably addressed by AstraZeneca’s Rebekah Martin.
Serving as senior vice president of reward and inclusion at AstraZeneca, Rebekah discussed how the pharmaceutical industry approaches the promotion of diversity.
In an episode that was recorded in December 2020, she also talked about what inclusion and diversity mean to her company.
January 5, 2021
Episode two of the Alderley Park Discovery Podcast covers access to skills in the life sciences sector, with a focus on support for aspiring scientists and UK staffing trends.
In this instalment Dominic Tyer’s guests on the podcast are Sai Life Sciences’ head of global R&D Dean Edney, Joynes & Hunt’s managing director Steve Joynes and Dr Kath Mackay, managing director at Bruntwood SciTech’s Alderley Park.
December 21, 2020
In episode 27 of the pharmaphorum podcast I’m joined by Erin McEachren, who’s EU Regional Vice President at J&J Surgical Vision.
She talks about her priorities at J&J, having joined the company six months ago, the current state of the medical devices sector and some of the trends she’s keeping a close eye on.
November 30, 2020
In episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently took up the position of CEO at the Paris-based biopharmaceutical company Pharnext.
October 30, 2020
GlaxoSmithKline’s Nucala (mepolizumab) last month became the first and only biologic treatment approved in the US for Hypereosinophilic Syndrome (HES).
It’s part of the company’s focus on eosinophil-driven diseases and ahead of that regulatory milestone I spoke with Tiffany Robinson-Smith, who’s global medical affairs lead for biologics at GSK, about eosinophils and why they’re an important element of her company’s research programmes.